What development phase is Yoshipyrin in?

Yoshipyrin is FDA-approved (marketed).

What is the generic name of Yoshipyrin?

PROPYPHENAZONE is the generic (nonproprietary) name of Yoshipyrin.

Last reviewed 2026-04-20 · How we verify

Yoshipyrin (PROPYPHENAZONE)

FDA-approved withdrawn Small molecule Quality 5/100

Propyphenazone (Yoshipyrin) is a marketed analgesic that blocks the transient receptor potential cation channel subfamily A member 1, positioning it as a targeted pain management solution. Its key competitive advantage lies in its unique mechanism of action, distinguishing it from same-class competitors such as metamizole. The primary risk to Yoshipyrin's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.

At a glance

Generic name	PROPYPHENAZONE
Drug class	propyphenazone
Target	Transient receptor potential cation channel subfamily A member 1
Modality	Small molecule
Therapeutic area	Pain
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Yoshipyrin CI brief — competitive landscape report
Yoshipyrin updates RSS · CI watch RSS